Xceed launches Strategic Collaborator program

According to Xceed’s president and CEO, David Deems, the Strategic Collaborator program is a mutually beneficial agreement with a high-profile institution or investigator designed to propel the partners’ clinical research, while providing Xceed with additional real-world clinical-laboratory experience and access to critical research results.

The program is an integral part of the company’s strategy to add assays to its pipeline of condition- or pathway-specific Signature Chips that will be available both as catalog products and through Xceed’s Expression Services.

Through the program, Xceed will provide the Ziplex System or Expression Services to the collaborator at no or low cost, in return for a commitment for future publication, access to biomarker content, or assistance with product development or services.

Xceed has already committed to several other institutions under its Strategic Collaborator program and will be installing the Ziplex System at additional sites before year-end. The company’s goal is to have 10 Strategic Collaborator agreements in North America by the second quarter of 2008.

Daniel Farkas, executive director of the Center for Molecular Medicine, said: “The intersection of patient care and business represented by our international collaboration is central to the mission of the Center for Molecular Medicine. As translational medicine moves from the research laboratory to the clinic, technology that is affordable, reliable, and automated will be critical. We believe the Ziplex System is uniquely positioned to fulfill this need.”